Cheil Bio Co

Cheil Bio Co LT Debt/Equity

Delisted·Feb 25, 2026

Long-Term Debt to Equity Ratio of Cheil Bio Co (052670.KQ) as of Nov 17, 2026.

LT Debt/Equity

0.00

YoY

144.80%

Last updated:

Long-Term Debt to Equity Ratio of Cheil Bio Co is 2023 0.00 . Long-Term Debt to Equity Ratio of Cheil Bio Co was 2022 0.00 . It decreases by 144.80% higher compared to the previous year.

The Cheil Bio Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2016
0.00 KRW
Jan 1, 2017
0.00 KRW
Jan 1, 2018
0.00 KRW
Jan 1, 2019
0.00 KRW
Jan 1, 2020
0.00 KRW
Jan 1, 2021
0.00 KRW
Jan 1, 2022
0.00 KRW
Jan 1, 2023
0.00 KRW
The Cheil Bio Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.00+144.80%
0.00—
0.00-100.00%
0.00-89.54%
0.00—
0.00—
0.00—
0.00-100.00%
0.01-74.83%
0.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cheil Bio Co Stock analysis

What does Cheil Bio Co do? Cheil Bio Co., Ltd. generates revenue through the production and sale of veterinary products for pigs, cattle, chickens, cows, and aquatic animals. The company offers antibiotics, antimicrobials, lactobacillus, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, and diagnostic kits including ELISA test kits, virus test kits, and DNA kits. These products are primarily sold to the domestic market, targeting livestock farmers and veterinary clinics. The firm also provides feed additives as part of its product portfolio. The company's product range includes specialized solutions for cattle, pigs, chickens, pets, and other animals, with a focus on health management and disease prevention. Veterinary clinics and livestock farms form the core customer segments, purchasing antibiotics, vaccines, and diagnostic tools to maintain animal health. The domestic market remains the primary sales channel, with no mention of international distribution. Cheil Bio's offerings are designed to address common health challenges in livestock, such as infections and parasitic infestations, through both preventive and therapeutic products. The inclusion of diagnostic kits like ELISA and DNA tests supports advanced veterinary care, enhancing the company's value proposition for professional animal health providers. Cheil Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cheil Bio Co stock

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Cheil Bio Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Cheil Bio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cheil Bio Co

All Key Metrics — Cheil Bio Co